Description
Isturisa (osilodrostat) is a prescription medication used to treat adults with Cushing’s disease who have failed or cannot have surgery. It is a steroidogenesis inhibitor that works by blocking an enzyme called 11-beta-hydroxylase, which is involved in the production of cortisol, a hormone that regulates various bodily functions. By reducing cortisol levels, Isturisa can improve the symptoms of Cushing’s disease.
Uses:
Isturisa is used to treat adults with Cushing’s disease who have failed or cannot have surgery.
Storage Conditions:
Isturisa should be stored at room temperature between 68°F and 77°F (20°C and 25°C) in its original container. It should be protected from moisture and light.
Mechanism of Action:
Isturisa is a steroidogenesis inhibitor that works by blocking the enzyme 11-beta-hydroxylase, which is involved in the production of cortisol. By reducing cortisol levels, Isturisa can improve the symptoms of Cushing’s disease.
HOW TO USE:
Isturisa should be taken orally, once in the morning with food. The initial dose is 2 mg twice daily, with dosage adjustments based on individual response and tolerance. Patients should take the medication at the same time each day. If a dose is missed, it should be taken as soon as possible, but not later than 6 hours before the next scheduled dose.
Precautions:
• Patients should inform their healthcare provider of any medical conditions they have, especially liver problems.
• Isturisa may increase the risk of adrenal insufficiency, a condition in which the adrenal glands do not produce enough cortisol. Patients should be monitored for signs and symptoms of adrenal insufficiency.
• Isturisa may interact with other medications, including hormonal contraceptives and drugs that affect cytochrome P450 enzymes. Patients should inform their healthcare provider of all the medications they are taking before starting Isturisa.
Drug Interactions:
• Isturisa may interact with other medications, including hormonal contraceptives, ketoconazole, rifampin, and drugs that affect cytochrome P450 enzymes.
• Patients should inform their healthcare provider of all the medications they are taking before starting Isturisa.
Contraindications:
• Isturisa should not be used in patients with hypersensitivity to the medication or its components.
• It is not recommended for use in patients with severe liver impairment.
• Isturisa should not be used in patients who are pregnant or breastfeeding.
Overdose:
There is limited information on the overdose of Isturisa. However, patients who take a higher-than-prescribed dosage of Isturisa should seek medical attention.
Adverse Reactions:
The most common adverse reactions experienced by patients taking Isturisa include nausea, headache, fatigue, adrenal insufficiency, and edema. Other potential side effects include liver enzyme elevations and QT prolongation. Patients should contact their healthcare provider if they experience any unusual symptoms while taking Isturisa.
In conclusion, Isturisa is a steroidogenesis inhibitor that treats Cushing’s disease in adults who have failed or cannot have surgery by blocking the production of cortisol. It is taken orally once in the morning with food and dosage adjustments are based on individual response and tolerance. Before taking Isturisa, patients should inform their healthcare provider of any medical conditions they have, medications they are taking, and pregnancy or breastfeeding status. Adverse reactions may include nausea, headache, fatigue, adrenal insufficiency, and edema. Isturisa should not be used in patients with severe liver impairment, hypersensitivity to the medication, pregnancy, or breastfeeding.
Reviews
There are no reviews yet.